ATAI News and Press, ATAI Life Sciences N.V. From 10/11/21

NEW YORK, Oct. 11, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the launch of PsyProtix, a new platform company formed with Chymia LLC, a ...

FN Media Group Presents USA News Group News Commentary Vancouver, BC –September 28, 2021 – USA News Group – New clinical trials based out of Australia are exploring the therapeutic benefits of psychedelics (which are currently illegal substances), i...

Psychedelics could soon revolutionize the $2.5 trillion mental health market. In fact, according to co-CEO of the ATMA Journey Centers, David Harder, a quoted in a company press release, “The surge in demand for alternative options to traditional mental health support have fueled...

VANCOUVER – FlyOnWallStreet – New clinical trials based out of Australia are exploring the therapeutic benefits of psychedelics (which are currently illegal substances), in what’s been described as a “ paradigm shifter ” for psychiatry. In particul...

NetworkNewsWire Editorial Coverage : The emergence of psychedelic therapies as a popular investment a few years ago was mostly underscored by investors that rode the cannabis wave seeing a brand-new opportunity with drugs such as psilocybin, LSD, MDMA, DMT, and others to address hard-to-tre...

NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- DemeRx IB, Inc. ("DemeRx"), an atai Life Sciences (Nasdaq: ATAI) ("atai") platform company focused on developing ibogaine for the treatment of opioid use disorder (OUD), today announced that the first subjects have been dosed in a Phase 1/2a clin...

Gainers: ABCL +19.8%. TCRR +7.4%. ATAI +6.7%. FANG +4.9%. VCYT +4.7%. Losers: KYMR -7.6%. GRTS -5.1%. JNCE -4.4%. GDS -3.4%. AMTX -3.3%. For further details see: ABCL, TCRR, KYMR and GRTS among after hours movers

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 15, 2021 – The damage done by the opioid epidemic has caused families grief and loss, but recent developments in the case against Purdue Pharma will see some restitution fo...

NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced it has entered into an amended and restated loan agreement (“...

NEW YORK and BERLIN, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Perception Neuroscience (Perception), an atai Life Sciences (atai) biopharmaceutical company focused on developing innovative therapies in neuropsychiatric diseases, today announced the initiation of a Phase 2a clinical study to ev...